Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Programmed death‐ligand 1 (PD‐L1) expression status is inadequate for indicating nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline advanced lung cancer inflammation index (ALI) is reportedly associated with patient outcomes, we investigated whether the pretreatment...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Med
Main Authors: Shiroyama, Takayuki, Suzuki, Hidekazu, Tamiya, Motohiro, Tamiya, Akihiro, Tanaka, Ayako, Okamoto, Norio, Nakahama, Kenji, Taniguchi, Yoshihiko, Isa, Shun‐ichi, Inoue, Takako, Imamura, Fumio, Atagi, Shinji, Hirashima, Tomonori
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2017
Fag:
Clinical Cancer Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5773945/
https://ncbi.nlm.nih.gov/pubmed/29150906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1234
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker